2017. ISPOR European Congress – Estimating utilities/disutilities for high risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events

Hall F, De Freitas H, Kerr C, Ito T, Nafees B, Lloyd A, et al. Estimating utilities/disutilities for high risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. Value Health; 2017 Oct-Nov;20(9):A448. Presented at: ISPOR 20th European Meeting: November 4-8, 2017; Glasgow, UK.